Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00287066 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 22
- Enrollment target
NCT00287066 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 22 participants.
The verdict
NCT00287066, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 22 participants
- Enrollment target
Study Summary
To assess the impact of inhalation of insulin on glucose disposition in patients with type 1 diabetes
Interventions
- DRUG Regular Human Insulin
- DRUG Inhaled Human Insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00287066
The ClinicalTrials.gov registry entry for NCT00287066 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Regular Human Insulin is the first listed.
NCT00287066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00287066 about?
NCT00287066 is a clinical study titled "A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition". To assess the impact of inhalation of insulin on glucose disposition in patients with type 1 diabetes
What is the current status of trial NCT00287066?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 22 participants. The study started on 2006-02. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00287066?
The interventions under investigation include: Regular Human Insulin (DRUG), Inhaled Human Insulin (DRUG).
Who is sponsoring clinical trial NCT00287066?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.